Brajesh Kumar

Abstract:

In 1965, Bangham et al. rst described the phospholipid vesicles. ese were later called liposomes. Use of liposome as a potential drug carrier was put forth and investigated by Bangham in the early 1970s. Since then applicability of liposomes as a drug delivery systems (DDS) has been intensively investigated. Pharmaceutical, cosmetics, and food industries are the major bene ciaries of the 50 years of research in this area. Several nanocarriers like liposomes, nanoparticles, and micelles have been shown to deliver small molecule drugs and peptides at the intended site of action with improved potency and reduced toxicity. ey are of particular interest for the delivery of promising molecules where stability, aqueous solubility, and nonspeci c toxicity are the major concerns. Research in the eld of liposome as DDS has resulted in about 11 liposomal drug formulations approved by FDA for clinical application. Many of these formulations have been approved for hard to treat cancers in advanced stages. Also, there are around 16 liposome-based formulations at di erent stages of clinical trials. However, translation of liposome assisted drug delivery platforms from bench to bedside has not moved at the same pace as expected from numerous positive results available in the literature. e major reason, among others, for the lack of fast progress on the clinical application part has largely been attributed to the synthesis of liposomes. Synthetic methods that can easily be scaled-up to clinical scale are much needed. A good synthetic method can also solve the problems associated with batch to batch variability. Many liposome formulations have been shown to be …

Año de publicación:

2004

Keywords:

Fuente:

google